Jevtana

DRUG3 trials

Sponsors

howard safran, Gustave Roussy, Cancer Campus, Grand Paris, Bayer

Conditions

EsophagealGastric CancerGastrooesophageal CancerMetastatic Castration-resistant Prostate CancerProstate Cancer, Castration Resistant

Phase 2

Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen

TerminatedNCT01365130

howard safranEsophageal, Gastric Cancer, Gastrooesophageal Cancer

Start: 2011-06-30End: 2013-08-31Updated: 2019-04-12

Phase 3

Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer

CompletedNCT02044354

Gustave Roussy, Cancer Campus, Grand ParisMetastatic Castration-resistant Prostate Cancer

Start: 2014-05-22End: 2017-12-22Updated: 2026-04-01

Unknown Phase

Multi-academic Center Study of Xofigo Patients

CompletedNCT03419442

BayerProstate Cancer, Castration Resistant

Start: 2018-12-03End: 2019-10-22Updated: 2020-10-22

Related Papers

Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.

2021-11-1420 citations

Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2019-05-202 citations